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enoxaparinEdoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efﬁcacy. In a multicenter, phase II study,
264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin
2000 IU (20-mg) twice daily for 11–14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72),
and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P = 1.00). Edoxaban-induced
prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time
were proportional to plasma edoxaban concentration.Major or clinically relevant non-major bleeding incidences
were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P =
1.00). Once-daily edoxaban showed similar efﬁcacy and safety to enoxaparin for prevention of thromboembolic
events in patients undergoing THA.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nd-sa/3.0/).Patients undergoing major orthopedic surgery are at high risk of
postoperative venous thromboembolism (VTE). The incidence of
asymptomatic deep vein thrombosis (DVT) and symptomatic VTE in
patients undergoing elective total hip arthroplasty (THA) is 40%–60%
and 2%–5%, respectively [1]. Therefore, aggressive prophylaxis with
anticoagulants including low-molecular-weight heparins (LMWHs),
fondaparinux, or vitamin K antagonists (eg, warfarin) is recommended
for patients following major orthopedic surgery [1].
The occurrence of VTE post surgery in the Japanese population had
been perceived to be considerably low; however, more recent data have
demonstrated an increasing incidence of VTE in patients undergoing
orthopedic surgery [2,3]. In a prospective, epidemiologic study, the
incidence of DVT was 22.6% in patients undergoing THA without
prophylactic anticoagulation [2]. Similarly, in a recent randomized
clinical trial, the incidence of VTE in Japanese patients undergoing THA
was 33.8% in the placebo group [3]. The anticoagulants enoxaparin
sodium and fondaparinux sodium have been approved in Japan at doses
of 20 mg twice daily and 2.5 mg once daily, respectively, for the
preventionofVTE inpatientsundergoingorthopedic surgeryof the lower
limbs such as THA, total knee arthroplasty (TKA), and hip fracture
surgery [4,5]. The currently available anticoagulants, however, arehis article can be found at doi:
hima-ku, Osaka 553-0003, Japan.
Inc. This is an open access article uassociated with several limitations. LMWHs and fondaparinux require
parenteral administration, and vitamin K antagonists display an
unpredictable pharmacokinetic (PK)/pharmacodynamic (PD) proﬁle,
numerous food and drug interactions, and genetic variability in patient
responses, necessitating frequent monitoring and dosage adjustments
[6,7]. Consequently, there is a need for new anticoagulants that can be
administered orally, havemore predictable PK/PD, and have comparable
or better safety and efﬁcacy than the existing anticoagulants.
Edoxaban is an oral, selective, direct factor Xa (FXa) inhibitor [8]
which has been evaluated for the prevention and treatment of
thromboembolic events [9,10]. Edoxaban is rapidly absorbed, with an
oral bioavailability of approximately 60% and a half-life of 8–10 hours,
and it demonstrates predictable and linear PK/PD [11,12]. Previous
phase II studies in patients undergoing THA [9] and TKA [13]
demonstrated that edoxaban was safe and effective for thrombopro-
phylaxis across a wide range of doses. The aim of the present study
was to evaluate the efﬁcacy, safety, and dosage regimen of edoxaban
in patients undergoing THA in Japan and Taiwan.
Materials and Methods
Study Design
This was a randomized, active-controlled, multicenter, parallel-
group, double-blind, phase II trial, conducted in Japan and Taiwan, tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nd-sa/3.0/).
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sodium for the prevention of VTE after THA. The study was conducted
in compliance with the Declaration of Helsinki Guidelines
for Good Clinical Practice or Guidelines for the Conduct of Clinical
Trials of Drugs. The protocol and informed consent forms were
reviewed and approved by the institutional review board. All patients
provided written informed consent before undergoing any study-
related examinations.
Study Population
Patients aged 20 to b85 years undergoing unilateral THA were
eligible for the study. Primary exclusion criteria included revision THA
or bilateral THA; history of intracranial bleeding, comorbid intraocular
bleeding, or intracranial malignant tumor; comorbid gastrointestinal
bleeding or peptic ulcer that occurred within 90 days before the
day of informed consent; history of symptomatic DVT or pulmonary
embolism (PE); patients weighing b40 kg; use of antithrombotic
therapy; severe renal disorder (creatinine clearance b30 mL/min); or
evidence of hepatic dysfunction (L-aspartate aminotransferase [AST]
or L-alanine aminotransferase [ALT] ≥2× upper limit of normal [ULN]
of the study site, total bilirubin ≥1.5× ULN of the study site).
Treatment Allocation and Schedules
Patients were randomly assigned to 1 of the following 3 treatment
groups: oral, double-blind edoxaban 15 or 30 mg once daily or open-
label, subcutaneous enoxaparin sodium 2000 IU (20 mg) twice daily
for 11-14 days. Patients were randomized to treatment groups using
the speciﬁcations of dynamic allocation procedures. After obtaining
written informed consent from the patients, the investigator or
subinvestigator completed a primary registration form before surgery
and a secondary registration form after surgery for eligible patients,
and faxed the registration forms to the patient registration center.
After secondary registration, the patient registration center assigned a
number to each patient using the biased coin-based method with the
study site as a factor to adjust the assignment. The study drugmatching
the case number was prescribed to the patient by the investigator
or subinvestigator.
If patients were randomized to 1 of the 2 edoxaban arms, the dose
of edoxaban was double-blinded; patient assignment to the enox-
aparin sodium arm was not blinded. Edoxaban and matching placebo
tablets were administered 6–24 hours after surgery with the
edoxaban tablet administered on the morning of the following day for
11–14 days. Enoxaparin sodium was started within 24–36 hours after
surgery, followed by dosing every 12 hours for 11–14 days. Treatment
compliance was assessed by clinical interviewwith patients and on the
number of unused drugs.
Bilateral venographywas performed within 24 hours after the end
of the study treatment or within 96 hours after discontinuation of the
study treatment. If venography could not be performed within
24 hours for reasons such as difﬁculty in establishing an intravenous
line, it was performed within 96 hours. If DVT or PE was suspected
based on clinical signs or symptoms observed during the period from
initiation of the study treatment to the target date of venography at
the end of the study treatment, the presence of DVT was conﬁrmed by
ultrasonography, venography, or computed tomography (CT) scan. PE
was conﬁrmed by pulmonary scintigraphy, pulmonary arteriography,
or CT scan. The study treatment was discontinued and the appropriate
intervention was used if DVT or PE was conﬁrmed by imaging test. In
the absence of DVT or PE, the study treatment was continued and
venographywas performedwithin 24 hours after the end of the study
treatment. An independent thromboembolic event assessment
committee that was blinded to the clinical conditions evaluated
thromboembolic events based on the radiographic images.Study Endpoints
The primary efﬁcacy endpointwas the incidence of thromboembolic
events (composite of symptomatic or asymptomatic DVT or symptom-
atic PE). The secondary efﬁcacy endpoints included the composite
incidence of symptomatic DVT, proximal DVT, symptomatic PE, or death
related to VTE (DVT or PE); incidence of asymptomatic or symptomatic
DVT; symptomatic or proximal DVT; symptomatic PE; VTE-related
deaths; and all-cause deaths.
The primary safety endpoints were the incidence of major
bleeding, clinically relevant non-major (CRNM) bleeding, and major
or CRNM bleeding. Secondary safety endpoints included the incidence
of all bleeding events (major, CRNM, and minor bleeding), adverse
events (AEs), and adverse drug reactions (ADRs). Major bleeding was
deﬁned as life-threatening bleeding, bleeding requiring repeated
surgery, bleeding into critical organs (retroperitoneal, intracranial,
intraocular, or intrathecal), clinically overt bleeding that led to a
decrease in hemoglobin of N2 g/dL or the need for transfusion of N4
units (1 unit = 200 mL) of blood. CRNM bleeding was deﬁned as
bleeding not meeting the criteria for major bleeding and included
hematoma of at least 5 cm in diameter, epistaxis or gingival bleeding
lasting at least 5 minutes, gastrointestinal bleeding, gross hematuria
persistent after 24 hours of onset, or other bleeding that was assessed
to be clinically signiﬁcant. All other bleeding episodes that did not fall
under the category of major or CRNM bleeding were classiﬁed as
minor bleeding. An independent bleeding event assessment commit-
tee, blinded to the clinical conditions, evaluated bleeding events.
PK/PD Assessments
Blood samples for plasma edoxaban concentrations, PD indices
(prothrombin time [PT], PT expressed as international normalized
ratio [PT-INR], and activated partial thromboplastin time [aPTT]), and
biomarkers (D-dimer, prothrombin fragment 1 + 2 [F1 + 2], thrombin
anti-thrombin III complex [TAT], soluble ﬁbrin, and plasmin-α2-
plasmin inhibitor complex [PIC]) were collected at pre-surgical
examination (baseline), on day 7 (pre-dose and 1–3 hours post-dose),
and on the last day of study treatment (pre-dose) or at the time of
discontinuation. Plasma concentrations of edoxaban were measured
using a validated liquid chromatography tandem mass spectrometry
method at the drug concentration assay facility. The lower limit of
quantitation was 1 ng/mL.
Sample Size and Statistical Analysis
The sample size is based on the precision of the 95% conﬁdence
interval (CI) of the difference between groups of incidence of VTE.
Assuming that the incidence of VTE in both groups was 20%, 53
evaluable subjects per dose group could be estimated for the
incidence of VTE with a 95% CI and precision of 15.2%. The planned
number of subjects was set at 70 subjects assuming that venography
would not be assessable for approximately 20% of the subjects.
Analyses of the efﬁcacy endpoints were performed in the full
analysis set (FAS). The FAS was deﬁned as all patients enrolled in the
studywho received at least 1 dose of study drug and had no signiﬁcant
Good Clinical Practice violations. Patients who did not develop
symptomatic DVT or PE and did not undergo venography were
excluded from the FAS. The incidence of thromboembolic events and
95% CIs were calculated for each treatment group. The difference
between the edoxaban 15- and 30-mg groups and the 95% CI were
also calculated. For reference, the differences between the enoxaparin
sodium group and each edoxaban group and the 95% CI of each were
calculated. A paired comparison of the incidence of thromboembolic
events between the treatment groups was performed using the χ2 test
or Fisher’s exact test.
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the FAS with valid PD indices, biomarkers, or plasma edoxaban
concentration measured at 1 or more time points and excluded those
with exclusion criteria, prohibited concomitant medications
or therapies, study treatment compliance rate b80%, or deviations
from the inclusion criteria. Summary statistics were calculated for PD,
biomarkers, and PK.
The safety analysis set included patients who received at least 1
dose of the study drug and had safety data after the start of study
treatment. The incidence of major, CRNM, and major or CRNM
bleeding and the 95% CI were calculated by treatment group. The
difference in the incidence between the treatment groups and the 95%
CI was also calculated. A paired comparison between the treatment
groups was performed using the χ2 test or Fisher’s exact test.
Results
Study Population
From June to December 2008, 264 patients were randomized to
edoxaban 15 mg once daily, edoxaban 30 mg once daily, or
enoxaparin sodium 2000 IU twice daily (Fig. 1). A total of 243
patients completed the study. Demographic and baseline character-
istics of the patients are shown in Table 1. The mean age was
60.3 years and themean BMIwas 23.9 kg/m2. Therewere no clinically
relevant differences in demographic or baseline characteristics
between the treatment groups. In addition, the duration from the
end of surgery to the start of study treatment was longer in the
enoxaparin sodium group than in the edoxaban groups, as expected
from the study design. Most of the participating centers were in Japan
andmost patientswere of Japanese descent. The overall compliance toFig. 1. Patient dstudy treatment was 100% in the edoxaban 15- and 30-mg groups and
95.9% in the enoxaparin sodium group.
Efﬁcacy
The primary endpoint, incidence of thromboembolic events
(composite of symptomatic or asymptomatic DVT, or symptomatic
PE) was 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) in the edoxaban 15-
and 30-mg groups and the enoxaparin sodium group, respectively
(Table 2). The incidence was low in all 3 treatment groups and no
statistically signiﬁcant difference was noted between the treatment
groups (Fisher’s exact test: P = 1.000). The thromboembolic events
were all distal asymptomatic DVT. There were no occurrences of
symptomatic or proximal DVT, symptomatic PE, VTE-related deaths,
or all-cause deaths in any of the treatment groups.
Pharmacodynamics and Pharmacokinetics
On day 7, PT, PT-INR, and aPTT were prolonged at 1–3 hours post-
dose in both edoxaban dose groups (Fig. 2A, B, C); no prolongation
was observed in the enoxaparin sodium group. The prolongation
observed in the edoxaban groups was directly proportional to the
increased plasma edoxaban concentration.
Biomarkers
D-dimer and F1 + 2 levels were decreased in the edoxaban 30-mg
group compared with the edoxaban 15-mg group and enoxaparin
sodium groups (Fig. 3A, B). There were no obvious differences in the
degree of the decrease in TAT levels between the treatment groups
(Fig. 3C). Soluble ﬁbrin median levels were lower in the edoxabanisposition.
Table 1
Demographic and Baseline Characteristics (Full Analysis Set).
Characteristic
Edoxaban Enoxaparin
Sodium
(n = 74) Test15 mg (n = 78) 30 mg (n = 72)
Age (y) Mean (SD) 61.3 (10.3) 60.6 (9.6) 58.9 (10.7) P = 0.330a
Sex, n (%) Female 63 (80.8) 69 (95.8) 59 (79.7) P = 0.009b
Weight (kg) Mean (SD) 57.9 (9.4) 57.6 (10.0) 56.7 (10.1) P = 0.744a
BMI (kg/m2) Mean (SD) 24.1 (2.9) 24.3 (3.6) 23.4 (3.9) P = 0.279a
Creatinine clearance (mL/min) Mean (SD) 91.3 (27.5) 94.8 (28.0) 93.5 (30.1) P = 0.754a
Duration of surgery (h:m) Mean (SD) 1:47 (0:37) 1:47 (0:32) 1:57 (0:43) P = 0.173a
Presence of bone cement use, n (%) Present 18 (23.1) 13 (18.1) 19 (25.7) P = 0.532b
Method of anesthesia
(multiple answers were allowed), n (%)
General anesthesia 71 (91.0) 65 (90.3) 65 (87.8) P = 0.797b
Epidural anesthesia 34 (43.6) 37 (51.4) 32 (43.2) P = 0.535b
Lumbar anesthesia (spinal anesthesia) 25 (32.1) 27 (37.5) 28 (37.8) P = 0.704b
Others 8 (10.3) 5 (6.9) 3 (4.1) P = 0.331b
Physiotherapy (multiple answers were allowed), n (%) Intermittent pneumatic compression
therapy (foot sole)
37 (47.4) 36 (50.0) 30 (40.5) P = 0.493b
Intermittent pneumatic compression
therapy (lower legs and thigh)
32 (41.0) 27 (37.5) 29 (39.2) P = 0.907b
Elastic stockings 64 (82.1) 61 (84.7) 60 (81.1) P = 0.835b
Duration from the end of surgery
to the start of study treatment (h:m)
Mean (SD) 21:12 (2:40) 21:38 (2:03) 27:49 (3:21) P b 0.001
SD = standard deviation; BMI = body mass index; ANOVA = analysis of variance.
a One-way ANOVA’s F test.
b χ2 test.
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sodium group (Fig. 3D). There were no differences in the median
PIC levels between the treatment groups (Fig. 3E). There was no
correlation between D-dimer, F1 + 2, TAT, soluble ﬁbrin, or PIC and the
plasma edoxaban concentration.Table 2
Incidence of Thromboembolic Events (Full Analysis Set).
Edoxaban
15 mg (n = 78) 30 mg (n =
Primary endpoint (composite of asymptomatic DVT,
symptomatic PE, or symptomatic DVT)
3 (3.8) 2 (2.8)
95% CId 0.0 to 8.1 0.0 to 8.1
Secondary endpoints
Composite incidence of symptomatic DVT,
proximal DVT, symptomatic PE, death related to
VTE (DVT or PE)
0 (0.0) 0 (0.0)
Asymptomatic or symptomatic DVTe,f 3 (3.8) 2 (2.8)
95% CId 0.0 to 8.1 0.0 to 6.6
Symptomatic or proximal DVT 0 (0.0) 0 (0.0)
Symptomatic PE 0 (0.0) 0 (0.0)
VTE-related deaths 0 (0.0) 0 (0.0)
All-cause deaths 0 (0.0) 0 (0.0)
All data are n (%) unless indicated otherwise.
DVT = deep vein thrombosis; PE = pulmonary embolism; CI = conﬁdence interval; VTE =
a Incidence in the edoxaban 15-mg group − incidence in the edoxaban 30-mg group.
b Each edoxaban group − enoxaparin group.
c P = 1.000 using the Fisher’s exact test.
d 95% CI based on the normal approximation.
e Patients with assessable venography.
f All events were distal asymptomatic DVT.Safety Endpoints
The incidence of major or CRNM bleeding was 2.2% (2/89) in the
edoxaban 15-mg group, 1.2% (1/85) in the edoxaban 30-mg group,
and 2.3% (2/87) in the enoxaparin sodium group (Fig. 4). There was 1Difference in the Incidence
Between the Edoxaban 15- and
30-mg groups (%)a
Enoxaparin
Sodium
(n = 74)
Difference in the
Incidence Between
Edoxaban and
Enoxaparin Sodium
Groups (%)b72)
Edoxaban
15 mg 30 mg
1.1b 3 (4.1) −0.2c −1.3c
−4.6 to 6.8 0.0 to 8.5 −6.4 to 6.0 −7.2 to 4.6
0.0 0 (0.0) 0.0 0.0
1.1c 3 (4.1) −0.2c −1.3c
−4.6 to 6.8 0.0 to 8.5 −6.4 to 6.0 −7.2 to 4.6
0.0 0 (0.0) 0.0 0.0
0.0 0 (0.0) 0.0 0.0
0.0 0 (0.0) 0.0 0.0
0.0 0 (0.0) 0.0 0.0
venous thromboembolism.
Fig. 2. Time course of (A) PT, (B) PT-INR, and (C) aPTT. Triangles, squares, and circles indicate the arithmetic mean.+Value between 1.5× and 3× the interquartile range away from
the box; ⁎Value lying more than 3× the interquartile range away from the box. PT = prothrombin time; PT-INR = PT/international normalized ratio; aPTT = activated partial
thromboplastin time.
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30-mg group; it was classiﬁed as clinically overt bleeding accompanied
by a decrease in hemoglobin of N2 g/dL. The incidence of all bleeding
events (major, CRNM, and minor bleeding) was 18.0% (16/89) in the
edoxaban 15-mg group, 21.2% (18/85) in the edoxaban 30-mg group,
and 21.8% (19/87) in the enoxaparin sodium group.
The incidenceofAEswas lower in the edoxaban15-mg(65.2%, 58/89)
and 30-mg (70.6%, 60/85) groups than in the enoxaparin sodium (82.8%,
72/87) group. The incidence of severe AEs was 1.1% (1/87) in the
enoxaparin sodium group, with no severe AEs in the edoxaban 15- and30-mggroups. The severe AE that occurred in 1 patient in the enoxaparin
sodium group was prolonged hospitalization due to dislocation of joint
prosthesis. The incidence of ADRs was lower in the edoxaban 15-mg
(18.0%, 16/89) and 30-mg (25.9%, 22/85) groups than in the enoxaparin
sodium (52.9%, 46/87) group.
Edoxaban was associated with low incidence of ALT and/or AST
elevations compared with enoxaparin sodium. ALT levels were
elevated ≥3× ULN of the study site in 3 patients in the edoxaban
15-mg group, 2 patients in the edoxaban 30-mg group, and 9 patients
in the enoxaparin sodium group. AST elevations≥3× ULN of the study
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patients in the enoxaparin sodium group. Bilirubin levels ≥3× ULN
were not observed in any treatment group.Discussion
This study demonstrated that oral administration of the novel
direct FXa inhibitor edoxaban 15 and 30 mg once daily for 11–14 days
in Japanese and Taiwanese patients undergoing THA had an efﬁcacy
and safety proﬁle similar to subcutaneous enoxaparin sodium 2000 IU
twice daily for the prevention of thromboembolic events. The primary
endpoint of the composite of thromboembolic events was similar forFig. 3. Time course of (A) D-dimer, (B) F1 + 2, (C) TAT, and (D) soluble ﬁbrin, and (E) PIC. Tri
the interquartile range away from the box; ⁎Value lying more than 3× the interquartile ra
thrombin III complex; PIC = plasmin-α2-plasmin inhibitor complex.the 2 edoxaban dose groups and for enoxaparin sodium; all of the
events were distal asymptomatic DVT. Although the clinical efﬁcacy
endpoint did not show a signiﬁcant dose-related reduction of
thromboembolic events for edoxaban, the observed prolongation of
PT, PT-INR, and aPTT in the edoxaban groups was dose dependent and
displayed a linear relationship with increasing edoxaban concentra-
tions. These ﬁndings suggested that edoxaban has a predictable, dose-
related effect. In addition, the biomarkers D-dimer, F1 + 2, and soluble
ﬁbrin were lower with the edoxaban 30-mg regimen compared
with the edoxaban 15-mg or the enoxaparin sodium regimen,
indicating that edoxaban 30 mg once daily inhibits secondary
ﬁbrinolysis, thrombin formation, and acceleration of ﬁbrinogenesis
more effectively in patients undergoing THA.angles, squares, and circles indicate the arithmetic mean. +Value between 1.5× and 3×
nge away from the box. F1 + 2 = prothrombin fragment 1 + 2; TAT = thrombin anti-
Fig. 3 (continued).
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dependent reductions in VTE compared to dalteparin or to placebo in 2
dose-ranging studies of THA [14] and TKA [13], respectively. In a phase IIb
study conducted in Canada, Europe, and the United States in patients
undergoing THA, the incidence of VTE decreasedwith increasing edoxaban
doses (15–90 mg once daily), but there was no dose-related difference in
bleeding events [14]. Similarly, in a Japanese phase IIb study in patients
undergoing TKA, edoxaban (5–60 mg once daily) was associated with aFig. 4. Incidence of bleeding events.signiﬁcant dose-related reduction in VTEwithout a signiﬁcant dose-related
increase in major or CRNM bleeding compared with placebo [13].
The overall incidence of thromboembolic events in the present
study was lower than the estimate obtained in a placebo-controlled
study of enoxaparin sodium in Japanese patients undergoing THA
[15]. The reported incidence of VTE in Japanese patients was 25.9% in
the enoxaparin sodium 20-mg once-daily group, 33.8% in the
enoxaparin 40-mg once-daily group, and 20% in the enoxaparin
sodium 20-mg twice-daily group versus 41.9% in the placebo groups
[15]. It is possible that differences in the incidence of thromboembolic
events between the present study and the enoxaparin sodium study
could be related to the differential use of mechanical DVT prevention
techniques (ie, absence of intermittent pneumatic compression in
53.7% of patients in the earlier study [15] versus implementation of
intermittent pneumatic compression therapy of the foot sole and of
the lower legs and thigh by 40.5% and 39.2% of patients, respectively,
and use of elastic stockings by 81.1% of patients in the present study.)
In the present study, there were no signiﬁcant differences in the
incidence of major and CRNM bleeding between the edoxaban 15-
and 30-mg groups. The absence of a signiﬁcant increase in bleeding
across the dose range is consistent with the results obtained in
previous edoxaban studies [13,14] In contrast, dose-ranging studies
with other FXa inhibitors have reported a signiﬁcant dose responsewith
respect to bleeding. In a phase II study comparing once-daily
rivaroxaban with enoxaparin for VTE prevention after elective hip
arthroplasty, rivaroxabanwas associatedwith similar efﬁcacy across the
dose range while demonstrating a signiﬁcant dose-response relation-
shipwith respect tomajor postoperative bleeding [16]. Another phase II
study evaluating the safety and efﬁcacy of apixaban demonstrated that
increased efﬁcacyof apixaban across thedose rangewas associatedwith
an increased incidence of total bleeding events [17].
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comparable to that of enoxaparin sodium. The incidence of all bleeding
events (major, CRNM, and minor bleeding) was lower in the edoxaban
15-mg group compared with the edoxaban 30-mg group and
enoxaparin sodiumgroup,whichwere similar. Theseﬁndings suggested
that bleeding risk with edoxaban is similar to or lower than that with
enoxaparin sodium. The incidence of AEs was lower in the edoxaban
30-mg group compared with the enoxaparin sodium group. Taken
together, these results suggest that edoxaban 30 mg once daily is the
appropriate dosage regimen for the prevention of thromboembolic
events in patients undergoing unilateral THA.
In summary, this study demonstrated that oral administration of
edoxaban has efﬁcacy similar to enoxaparin sodium for the prevention
of thromboembolic events in Japanese and Taiwanese patients
undergoing THA. The enoxaparin sodium dose used in this study is
the approved dose in Japan (20 mg twice daily, equivalent to 2000 IU in
anti-FXa activity), which differs from that used in the United States
(30 mg twice daily) or Europe (40 mg once daily) for THA. The
incidence ofmajor or CRNMbleeding observed in the edoxaban 15- and
30-mg groups was comparable to that of enoxaparin sodium. However,
lower levels of the biomarkers D-dimer, F1 + 2, and soluble ﬁbrin were
observed in the edoxaban 30-mg group. When both efﬁcacy and safety
are considered, the results suggest that edoxaban 30 mg once daily is
the appropriate dosage regimen for prevention of thromboembolic
events in patients undergoing THA.
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study investigators:M. Tsuji, K. Kitamura, T.Masuda, K. Sato, K. Oinuma,
M. Nakamura, T. Matsuda, S. Hasegawa, T. Mori, K. Uchiyama, A. Hyodo,
S. Kondo, F. Hashimoto, T. Matsumoto, T. Tani, M. Tsukamoto, H. Iwaki,
M. Kakiuchi, K. Nakata, S. Kushitani, S. Saito, H. Iida, H. Tokunaga,T. Matsubara, S. Abe, N. Ikeda, Y. Nanba, N. Shiota, J. Nakashiro,
K. Miyanishi, M. Naito, F. Higuchi, Y. Doiguchi, M. Nagayama, C.J. Wang;
sponsor representatives: T. Kimura (Project Leader Japan), K. Fujii
(Project Leader Taiwan), M. Fukuzawa (Study Leader Japan), H. Ushida
(Study Leader Taiwan), T. Sato (Statistician).References
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